Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2011-08-09
2011-08-09
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S085700, C424S093710
Reexamination Certificate
active
07993638
ABSTRACT:
In a cancer treatment combining cell therapy with chemotherapy, autologous CD8+T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating antigen-specific activated cytotoxic T lymphocytes. Such activated CTLs are administered to the patient in conjunction with a lymphodepletion and CTL maintenance regimen comprising a non-myeloblative but lymphdepleting agent, such as cladribine or denileukin diftitox, and interleukin-2 and interferon-α-2b stimulatory cytokines.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 4844893 (1989-07-01), Honsik
patent: 6225042 (2001-05-01), Cai et al.
patent: 6355479 (2002-03-01), Webb et al.
patent: 2004/0071671 (2004-04-01), Leturcq et al.
patent: WO95/22561 (1995-08-01), None
patent: WO 01/82963 (2001-11-01), None
patent: WO 03/057823 (2003-07-01), None
Dannull et al (Journal of Clinical Investigation, Dec. 2005, vol. 115, pp. 3623-3633.
Barnett, Brian et al. “Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential”, American Journal of Reproductive Immunology. New York, 1989, vol. 54, No. 6, Dec. 2005, pp. 369-377, XP002586724.
Koopmans, et al. “Porcine Fetal Ventral Mesencephalic Cells are Targets for Primed Xenoreactive Human T Cell Transplantation”, 2006, vol. 15, pp. 381-387.
Sun, et al. “The Interaction Defect of Accessory Molecules is Responsible for the Poor Ex Vivo Response to Human Antigens of Mouse T Helper Cells”, 2003, Scandanavian Journal of Immunology, vol. 58, pp. 59-66.
Patel, et al. “Class II MHC/Peptide Complexes Are Released from APC and are Acquired by T Cell Responders During Specific Antigen Recognition”, 1999, vol. 163, pp. 5201-5210.
Barzaga-Gilbert, et al. “Species Specificity and Augmentation of Responses to Class II Major Histocompatability Complex Molecules in Human CD4 Transgenic Mice”, Journal of Experimental Medicine, 1992, vol. 175, pp. 1707-1715.
Cai Zeling
Moriarty Ann
Peterson Per A.
Richards Jon M.
Canella Karen A
Janssen Pharmaceutica NV
LandOfFree
Cancer treatment combining lymphodepleting agent with CTLs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer treatment combining lymphodepleting agent with CTLs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment combining lymphodepleting agent with CTLs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711182